AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food, and beverage markets.
Courtesy of Aptar Pharma
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, will present its latest innovation, DF30Plus with COCe, at the Pharmapack Europe conference in Paris, to be held on February 10 and 11, 2016.
This new DF30Plus metering valve version incorporates a Cyclic-Olefin-Copolymer (COC) neck gasket to further enhance its performance. It is the result of continuous improvement to today's world leading DF30 technology platform.
DF30Plus with COCe: ultra-clean, robust and versatile
Aptar Pharma's DF30 metering valve technology platform has been the industry gold standard for more than 20 years and we are constantly striving to optimize our DF30 product offering.
COC is a well-known and characterized material used for injectable drug containers. COCe is a specific version of COC that has unique elastomeric properties while being ultraclean and inert.
The new version of DF30Plus that incorporates a neck gasket manufactured with COCe offers several key benefits:
For more information on DF30Plus, please visit our booth #612 or our website:
About Aptar Pharma
Aptar Pharma is a part of the AptarGroup family of companies, along with AptarBeauty + Home and Aptar Food + Beverage.
AptarGroup, Inc. is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food, and beverage markets.
AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. To learn more, visit www.aptar.com/pharma.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.